Abstract
Introduction
Central centrifugal cicatricial alopecia (CCCA) is a type of primary scarring alopecia characterized by hair loss on the vertex of the scalp. While treatment often focuses on reducing inflammation, no established standard of care exists. Early diagnosis and intervention are critical, as advanced stages with permanent follicular scarring are challenging to treat. Our study aims to assess CCCA treatment practices and provider confidence among dermatology residents and attendings in an urban academic setting. We further compare these real-world practices with existing literature.
Methods
We conducted a cross-sectional survey study of the commonly prescribed/recommended treatments for CCCA in 31 residents and attending physicians at two dermatology programs. Of those, 26 indicated that they see patients with CCCA, comprising 17 residents and nine attending physicians.
Results
Overall, the most frequently utilized therapies for CCCA were topical corticosteroids (TCS) (n = 26), designated as first-line by 90.5% of users, topical minoxidil (n = 24), used first-line by 77.3%, and intralesional corticosteroids (n = 24), used first-line by 65% of users. Oral tetracyclines were used by only 56% (n = 14) of respondents.
Discussion
Our findings mostly align with the current recommendations in the literature, focusing on reducing inflammation with topical and intralesional corticosteroids. Interestingly, topical minoxidil was used first-line by most respondents, possibly reflecting its greater accessibility to our patient population. The discrepancies in our findings may be reflective of variability in provider comfort in CCCA management, concern for side effects of systemic treatments, and presentations of later, “burnt-out” stages of CCCA.
Keywords: central centrifugal cicatricial alopecia, hair disorders, scalp inflammation, scarring alopecia, survey
Introduction
Central centrifugal cicatricial alopecia (CCCA) is a type of scarring alopecia that predominantly affects middle-aged women of African descent, characterized by hair loss at the vertex of the scalp in a centrifugal pattern, and affects an estimated 15% of Black women [1,2]. The pathogenesis is not well understood. CCCA involves premature desquamation of the inner hair root sheath, leading to an inflammatory cascade and eventual destruction of the follicle [3]. On histopathology, CCCA is characterized by the absence of the inner root sheath and the presence of compound follicular structures with perifollicular fibrosis [4]. CCCA is thought to have a multifactorial etiology with both genetic and environmental components, such as, traction-inducing hairstyles, bacterial scalp infections, and diabetes mellitus type 2 [5,6]. Management typically focuses on reducing inflammation and halting the progression of the scarring process [7]. Early diagnosis and intervention are crucial, as advanced stages with clinical perifollicular fibrosis are challenging to treat as the pilosebaceous units become permanently scarred. However, patients have reported several barriers to effective care for CCCA, including limited physician experience with CCCA or in managing ethnic hair and limited access to effective treatment options [8]. Currently, there are no published randomized controlled trials on treatment for CCCA or established clinical guidelines for the management of CCCA [7]. In 2024, Jackson et al. published a Delphi consensus survey proposing several treatment recommendations for CCCA based on input from 21 dermatologists with expertise in hair and scalp disorders [9]. Despite growing recognition of CCCA, there remains a paucity of data on how it is typically managed in clinical practice. Our study aims to assess CCCA treatment practices and provider confidence among dermatology residents and attendings in an urban academic setting. We further compare these real-world practices with existing literature, including the 2024 Delphi consensus. To our knowledge, this is the first survey-based study to evaluate current CCCA treatment practices.
Materials and methods
We conducted a cross-sectional, IRB-exempt survey study at the Albert Einstein College of Medicine/Montefiore Medical Center and St. Barnabas Hospital, located in New York. Albert Einstein College of Medicine Institutional Review Board issued approval 2022-14189. Prior to distribution, the questionnaire was peer-reviewed by two board-certified dermatologists. The questionnaire was distributed to all residents and attending physicians of the Dermatology Division/Department at both residency programs in October 2024 (Appendix 1). It was conducted online via a Qualtrics link for ease of access and distribution.
The survey consisted of 10 questions regarding the respondents (experience, confidence in treating CCCA, etc.) and up to 74 questions regarding CCCA treatment regimens, with conditional follow-up questions based on prior responses (Appendix 1). The questionnaire included a question asking to indicate the race, with response options: Asian, Black, Native Hawaiian or Other Pacific Islander, American Indian or Alaskan Native, and White participants. Treatment options specified in the survey reflected the most commonly used treatments for CCCA in the literature, including ketoconazole shampoo, ciclopirox shampoo, zinc pyrithione shampoo, selenium sulfide shampoo, topical corticosteroids, intralesional corticosteroids, topical minoxidil, oral minoxidil, oral finasteride, oral tetracyclines, light-emitting diode (LED) light therapy, platelet-rich-plasma (PRP), exosomes, compounded topical medications, and systemic corticosteroids [2,9]. Follow-up questions included, but were not limited to, the respondent’s likelihood of prescribing or recommending the treatment, confidence in its efficacy, and the concentration used. In addition to multiple-choice responses, respondents had an option to provide free-text comments. Data were summarized, and descriptive statistics were analyzed using Microsoft Excel, version 16.99.1 (Microsoft Corporation, Redmond, Washington, United States).
Results
The survey was distributed to a total of 35 providers, with 31 initiating the survey, resulting in a response rate of 88.6%. Of those, 26 indicated that they see patients with CCCA, comprising 17 residents and nine attending physicians (Table 1).
Table 1. Summary of patients seen by participants.
All data are reported as n (%).
SOC: skin of color; CCCA: central centrifugal cicatricial alopecia
| Parameters | Residents (n = 17) | Attendings (n = 9) | Combined (n = 26) |
| Percent of mix of SOC seen in your practice, n (%) | |||
| 25% | 0 (0) | 2 (22.2) | 2 (7.7) |
| 50% | 3 (17.7) | 3 (33.3) | 6 (23.1) |
| 75% | 9 (52.9) | 3 (33.3) | 12 (46.1) |
| >75% | 5 (29.4) | 1 (11.1) | 6 (23.1) |
| Number of CCCA patients seen per week, n (%) | |||
| 0 | 1 (5.9) | 0 (0) | 1 (3.8) |
| <3 | 15 (88.2) | 7 (77.8) | 22 (84.6) |
| 4 to 10 | 1 (5.9) | 1 (11.1) | 2 (7.7) |
| 11 to 20 | 0 (0) | 1 (11.1) | 1 (3.8 |
| Percent of your patients willing to use out-of-pocket therapies, n (%) | |||
| 0% | 2 (11.8) | 1 (11.1) | 3 (11.5) |
| <10% | 7 (41.2) | 3 (33.3) | 10 (38.5) |
| 25% | 4 (23.5) | 2 (22.2) | 6 (23.1) |
| 50% | 5 (23.5) | 2 (22.2) | 7 (23.1) |
| 75% | 0 (0) | 1 (11.1) | 1 (3.8) |
| Comfort with treating hair loss, n (%) | |||
| Very comfortable | 1 (5.9) | 3 (33.3) | 4 (15.4) |
| Comfortable | 7 (41.2) | 4 (44.4) | 11 (42.3) |
| Neutral | 8 (41.2) | 1 (11.1) | 8 (30.8) |
| Uncomfortable | 2 (11.8) | 1 (11.1) | 3 (11.5) |
| Comfort with treating CCCA, n (%) | |||
| Very comfortable | 0 (0) | 2 (22.2) | 2 (7.7) |
| Comfortable | 4 (23.5) | 4 (44.4) | 8 (30.8) |
| Neutral | 8 (47.1) | 2 (22.2) | 10 (38.5) |
| Uncomfortable | 5 (29.4) | 1 (11.1) | 6 (23.1) |
Most respondents reported seeing one to three CCCA patients per week (22/26, 84.6%), and the majority (24/26, 92.3%) indicated that at least 50% of their patient population were patients with skin of color (SOC). Most residents reported feeling neutral to uncomfortable with treating CCCA (13/17, 76.5%), while most attendings reported feeling comfortable to very comfortable with treating CCCA (6/9, 66.7%). Furthermore, 73.1% of respondents reported that the majority of their patients were unwilling to pursue out-of-pocket therapies. Figure 1 provides a summary of the CCCA treatments utilized by providers.
Figure 1. Summary of therapies for CCCA utilized by dermatology residents and attending physicians.
CCCA: central centrifugal cicatricial alopecia; LED: light-emitting diode; PRP: platelet-rich plasma; n: number of respondents
Medicated shampoos (ketoconazole, selenium sulfide, zinc pyrithione, ciclopirox)
Ketoconazole shampoo was the most frequently used (14/26, 53.8%), followed by zinc pyrithione (6/26, 23.1%), selenium sulfide (5/26, 19.2%), and ciclopirox shampoo (5/26, 19.2%) to treat CCCA. All respondents who reported using ciclopirox shampoo were residents (n = 5), with 60% (3/5) expressing a neutral level of confidence in its efficacy.
Other localized medications (topical corticosteroids, intralesional corticosteroids, topical minoxidil, compounded topical medications)
Figures 2-5 summarize the responses to questions regarding localized therapies used for CCCA. All respondents (26/26, 100%) reported using topical corticosteroids (TCS) in their treatment of CCCA, with clobetasol solution/foam being the most common formulation (9/21, 42.9%) and twice-daily application as the most prescribed frequency (14/25, 56%). All but one respondent reported using intralesional corticosteroids (24/25, 96%) (Figure 1), most commonly as triamcinolone acetonide 5 mg/cc (14/20, 70%). Nearly all respondents reported using topical minoxidil 5% (24/25, 96%). Compounded topical medications were only used by 20% (5/25) of respondents, most frequently combining topical minoxidil and finasteride (3/5, 60%) or compounding topical minoxidil at high concentrations >5% (3/5, 60%).
Figure 2. Localized therapies used for CCCA (general questions: likelihood of recommending/prescribing).
Question was only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy. “Other” responses include “with erythema and scale” for intralesional corticosteroids, and “adjunct” for topical minoxidil.
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Figure 3. Localized therapies used for CCCA (general questions: confidence).
Question was only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy.
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Figure 4. Localized therapies used for CCCA (general questions: dosage/frequency).
Question was only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy. Respondents could choose more than one answer, and therefore the sum of percentages may sum up to over 100%.
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Figure 5. Localized therapies used for CCCA, therapy-specific questions.
Questions were only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy. For the second question (“Which topical steroid do you most commonly use?”), “Other” responses include “betamethasone dipropionate gel” and “betamethasone dipropionate lotion.”
* denotes questions where respondents could choose more than one answer, and therefore the sum of percentages may sum up to over 100%.
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Systemic medications (oral minoxidil, oral finasteride, oral tetracyclines, systemic corticosteroids)
Figures 6-9 summarize the responses to questions regarding systemic therapies used for CCCA. Most respondents reported using oral minoxidil (20/25, 80%), although those who did commonly recommended this treatment as second-line (5/11, 45.5%). Oral finasteride was prescribed by only 8% (2/25), all in post-menopausal women. Oral tetracyclines, specifically doxycycline, were used by 56% (14/25), and of those, most used them as second-line therapy (7/14, 50%). The most common dosage was 100 mg twice daily (9/14, 64.3%). Systemic corticosteroids were rarely used (1/25, 4%), consisting of a single resident (Figure 1).
Figure 6. Systemic therapies used for CCCA (general questions: likelihood of recommending/prescribing).
“Other” responses for oral minoxidil include “adjunct,” and for tetracyclines include “depends on the amount of inflammation, scarring, extent, patient's age, etc.”
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Figure 7. Systemic therapies used for CCCA (general questions: confidence).
Question was only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy.
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Figure 8. Systemic therapies used for CCCA (general questions: dosage/frequency).
Question was only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy. Respondents could choose more than one answer, and therefore, the sum of percentages may sum up to over 100%.
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Figure 9. Systemic therapies used for CCCA, therapy-specific questions.
Questions were only asked if the respondent answered “yes” to recommending/prescribing the relevant therapy. For the first question (“Do you prescribe low-dose minoxidil in combination with topical minoxidil?”), “Other” responses for oral minoxidil include “patient dependent” and “sometimes.”
CCCA: central centrifugal cicatricial alopecia; n: number of respondents
Miscellaneous treatments (in-office LED light therapy, platelet-rich plasma, exosomes)
None of the respondents reported using LED light therapy, PRP, or exosomes for CCCA management. Overall, the most frequently utilized therapies for CCCA were topical corticosteroids (n = 26), designated as first-line by 90.5% of users (19/21), topical minoxidil (n = 24), used first-line by 77.3% (16/24), and intralesional corticosteroids (n = 24), used first-line by 65% (13/20) of users.
Discussion
This study captures real-world clinical approaches to the management of CCCA at two academic institutions and highlights variations in treatment preferences and confidence levels among residents and attending dermatologists.
Topical and intralesional corticosteroids are the mainstays of CCCA therapy, used to reduce inflammation and perifollicular edema of the scalp and to relieve symptoms including pruritus, tenderness, erythema, and scaling [10]. Nearly all respondents reported using either modality, and both were frequently designated as first-line therapies. Among the topical corticosteroids, clobetasol solution/foam was the most commonly prescribed type. For intralesional injections, 5 mg/cc of triamcinolone acetonide was the most commonly used concentration. These practices align with the Delphi consensus recommendations and the current literature, which emphasize that first-line therapy should primarily target inflammation to preserve the remaining hair [9,11].
Medicated antiseborrheic shampoos were utilized less frequently, with the most common being ketoconazole shampoo (n = 14). Although primarily known for its role as an antifungal agent, ketoconazole has also been shown to exhibit anti-inflammatory properties via inhibition of 5-lipoxygenase, supporting its use in non-fungal inflammatory scalp conditions [12]. Of the antiseborrheic shampoos, zinc pyrithione and ciclopirox-based shampoos have been suggested as better tolerated in African American women who chemically straighten their hair, as other formulations may contribute to dryness and hair breakage [13]. Comparatively, the dermatologists in the Delphi consensus by Jackson et al. did not reach agreement on the use of medicated shampoos [9].
Topical (n = 24) and oral minoxidil (n = 20) were widely utilized by respondents, reflecting provider efforts to promote hair growth alongside anti-inflammatory strategies [11]. Minoxidil, a vasodilator, has been shown to stimulate hair growth by shortening the telogen phase, prolonging the anagen phase, and increasing hair follicle size [14]. The Delphi consensus strongly supported the use of both topical and oral minoxidil as adjunctive therapies [9]. In contrast to these recommendations, most respondents in our study indicated using topical minoxidil as first-line therapy. In alignment with the consensus, oral minoxidil was more commonly used as a second-line or adjunctive therapy. We speculate that the more frequent use of topical minoxidil as a first-line therapy may be reflective of its over-the-counter availability and greater accessibility to our patient population. Although the efficacy of minoxidil in CCCA has not yet been established in randomized trials, its proposed benefit is thought to be due to stimulating intact follicles that have not yet been scarred and potentially treating a component of overlapping androgenetic alopecia (AGA) [15]. Histopathologic examinations of CCCA have shown the presence of follicular miniaturization, supporting the rationale for minoxidil use [4].
Compounded topical medications allow for the creation of formulations that are not typically found in commercially available products. Compounded topicals were only used by a small minority of the respondents (n = 5). The formulations reported to be prescribed by respondents were tacrolimus, minoxidil combined with finasteride, high-concentration minoxidil (>5%), metformin, and combined clobetasol, minoxidil, and tacrolimus. Metformin, an antidiabetic medication used for glycemic control, has been shown in case studies to promote hair growth in CCCA when applied topically [16]. Its proposed mechanism includes reducing circulating androgen activity and fibrosis through the mediation of adenosine monophosphate-activated protein kinase. Meanwhile, topical calcineurin inhibitors in CCCA may be beneficial in symptom alleviation from their anti-inflammatory effects by suppressing the synthesis of pro-inflammatory cytokines [17]. Overall, data on the efficacy of compounded topicals for CCCA are limited, and no specific recommendations for these medications reached agreement in the Delphi consensus [9].
Oral tetracyclines, specifically doxycycline, were reported to be used by approximately half of the respondents (n = 14), most commonly at a dosage of 100 mg twice daily. This dosing aligns with the Delphi consensus, which reached strong agreement on the use of doxycycline 200 mg daily for up to six months in adults with active CCCA [7]. Tetracyclines are bacteriostatic antimicrobial agents with anti-inflammatory effects, making them a therapeutic option in inflammatory scalp conditions [18]. Doxycycline use in CCCA has been supported by a 2024 retrospective study by Obi et al., which showed that patients who were given low-dose doxycycline in the initial management of CCCA in addition to topical/intralesional corticosteroids experienced greater hair regrowth compared to those who did not receive doxycycline [19]. We propose that the lower utilization of oral tetracyclines by the respondents may reflect hesitancy due to their frequent gastrointestinal side effects, such as nausea and diarrhea. Alternatively, this finding may indicate that some providers are seeing patients in later, “burnt-out” stages of CCCA where active inflammation is minimal.
In contrast, other systemic therapies, including oral finasteride (n = 2) and corticosteroids (n = 1), were sparsely used, which we postulate may be due to reluctance in prescription due to less evidence substantiating their use in CCCA and the risk of side effects. Finasteride, a 5α-reductase inhibitor, is a common treatment for AGA, and it functions by preventing the conversion of testosterone to the more potent androgen dihydrotestosterone. While finasteride has been used in postmenopausal women to treat AGA, finasteride is not approved by the United States Food and Drug Administration (FDA) in women, the primary demographic of patients with CCCA, and is forbidden in pregnant women due to the risk of abnormal sexual development of the fetus [20]. Oral corticosteroids, in short courses, have been suggested to be used in cases with active inflammation [7]; however, they carry a multitude of adverse effects, ranging from mild hypothalamic-pituitary axis suppression to risk of severe infections [21]. In CCCA, systemic corticosteroids may also have the potential for disease relapse upon tapering. Moreover, experts from the Delphi consensus strongly opposed the use of systemic corticosteroids for the management of CCCA [9].
Procedural therapies such as LED light therapy, PRP, and exosomes were not used by any respondents. This may reflect limited clinical evidence of these emerging therapies, lack of provider familiarity or access, and significant cost barriers to the patient, particularly in the context of a patient population that is largely unwilling or unable to pursue out-of-pocket therapies. LED light therapy, specifically low-level light therapy, is hypothesized to have an anti-inflammatory role through its proposed action on the cytochrome complex mitochondrial pathway [22]. A recent case series exploring the use of this therapy in patients with CCCA suggested potential benefit as an adjuvant therapy [23]. PRP, an autologous blood product with high concentrations of platelets, growth factors (GFs), and cytokines, is hypothesized to exert anti-inflammatory effects and stimulate new follicles via growth factors [24]. Exosomes, which are small membrane-bound extracellular vesicles, have an unclear mechanism of action but are proposed to modulate the hair cycle through paracrine signaling by promoting the transition from telogen to anagen and have anti-inflammatory properties [25,26]. However, exosome therapy is not approved by the FDA, which has issued consumer alerts regarding the unregulated nature of exosome products in the United States [27]. To date, evidence supporting the use of these emerging procedural therapies remains limited to a small number of case reports, underscoring the need for further clinical investigation before regular implementation into clinical practice.
Limitations and strengths
This study is primarily limited by its small sample size and the restriction of survey distribution to two dermatology residency programs, which may limit the generalizability of the findings. Additionally, the inclusion of both residents and attending physicians introduces the possibility of response bias, as there is a possibility that trainees may be influenced by the prescribing patterns and preferences of their supervising attendings. The cross-sectional design of the survey also carries the risk of sampling bias. Despite these limitations, this study is strengthened by its high response rate and offers additional perspective on CCCA management, particularly within a high SOC patient population. Our study also contributes to the limited body of literature on CCCA, a condition for which many providers continue to rely on anecdotal experience due to the lack of established, evidence-based guidelines for treatment. Future studies should aim to involve larger, multi-institutional cohorts to more comprehensively understand current CCCA treatment patterns to better inform clinical decision-making and guideline development.
Conclusions
This study provides valuable insight into treatment practices for CCCA by dermatology residents and attendings at a high-CCCA volume academic institution in the absence of standardized guidelines. While most approaches aligned with the current literature, there were some divergences in clinical practices, such as the use of topical minoxidil as a first-line therapy and a lower utilization of oral doxycycline compared to existing literature. Our data may reflect restricted access to therapies, variability in provider comfort in CCCA management, concern for side effects of systemic treatments, and presentations of later, “burnt-out” stages of CCCA. The results reinforce the need for randomized control trials to establish clinically validated treatment algorithms and improve physician confidence in managing this challenging disease.
Acknowledgments
The authors would like to thank Dr. Prince Adotama and Dr. Kristen Lo Sicco for their insightful feedback on the survey questions prior to distribution.
Appendices
Appendix 1
Table 2. CCCA questionnaire.
CCCA: central centrifugal cicatricial alopecia; PGY: post-graduate year; TAC: triamcinolone; LED: light-emitting diode; PRP: platelet-rich plasma
| Demographics: | |
| 1. What race do you identify with most? | a. American Indian or Alaskan Native |
| b. Asian | |
| c. Black | |
| d. Native Hawaiian or Other Pacific Islander | |
| e. White | |
| f. Prefer not to answer | |
| 2. What ethnicity do you identify with most? | a. Hispanic |
| b. Not-Hispanic | |
| c. Prefer not to answer | |
| 3. What type of location do you primarily practice in? | a. Urban |
| b. Suburban | |
| c. Rural | |
| 4. What type of setting do you primarily practice? | a. Solo (private practice) |
| b. Group (private practice) | |
| c. Multispecialty (either academics or private practice) | |
| d. Academic | |
| e. Government | |
| 5. How long have you been in practice: | a. 1-3 years |
| b. 4-9 years | |
| c. 10-14 years | |
| d. 15+ years | |
| e. Currently in training (PGY-1, PGY-2, PGY-3 or PGY-4)* Free response | |
| 6. What is the mix of SOC patients seen in your practice?: | a. None |
| b. <10% | |
| c. 25% | |
| d. 50% | |
| e. 75% | |
| f. >75% | |
| 7. How many central centrifugal cicatricial alopecia (CCCA) patients do you see per week?: | a. None |
| b. <3 | |
| c. 4-10 | |
| d. 11-20 | |
| e. More than 20 | |
| 8. What percentage of your patients are willing to use out-of-pocket therapies?: | a. None |
| b. <10% | |
| c. 25% | |
| d. 50% | |
| e. 75% | |
| f. >75% | |
| 9. How comfortable are you with treating hair loss? | a. Very comfortable (1) |
| b. Comfortable (2) | |
| c. Neutral (3) | |
| d. Uncomfortable (4) | |
| e. Very uncomfortable (5) | |
| 10. How comfortable are you with treating CCCA?: | a. Very comfortable (1) |
| b. Comfortable (2) | |
| c. Neutral (3) | |
| d. Uncomfortable (4) | |
| e. Very uncomfortable (5) | |
| The following questions are about therapies you use in practice: | |
| 1. Do you recommend/prescribe ketoconazole shampoo for CCCA? | a. No |
| b. Yes | |
| If yes to Q1: | |
| 1a. How likely are you to recommend/prescribe this treatment (ketoconazole shampoo)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 1b. How confident are you in the efficacy of this treatment (ketoconazole shampoo) to treat scaling, itchiness, inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 1c. What percentage of this therapy (ketoconazole shampoo) do you recommend/prescribe? | a. 1% |
| b. 2% | |
| 1d. What frequency of this therapy (ketoconazole shampoo) do you recommend/prescribe? | a. Daily |
| b. Three times a week | |
| c. Once a week | |
| d. As needed | |
| 1e. How often do you counsel patients on the side effects of dryness/brittleness of hair associated with ketoconazole use? | a. Always |
| b. Often | |
| c. Sometimes | |
| d. Not at all | |
| 2. Do you recommend/prescribe ciclopirox shampoo for CCCA? | a. No |
| b. Yes | |
| If yes to Q2: | |
| 2a. *How likely are you to recommend/prescribe this treatment (ciclopirox shampoo)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 2b. How confident are you in the efficacy of this treatment (ciclopirox shampoo) to treat scaling, itchiness, inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 2c. What frequency of this therapy (ciclopirox shampoo) do you recommend/prescribe? | a. Daily |
| b. Three times a week | |
| c. Once a week | |
| d. As needed | |
| 3. Do you recommend/prescribe zinc pyrithione shampoo for CCCA? | a. No |
| b. Yes | |
| If yes to Q3: | |
| 3a. *How likely are you to recommend/prescribe this treatment (zinc pyrithione shampoo)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 3b. How confident are you in the efficacy of this treatment (zinc pyrithione shampoo) to treat scaling, itchiness, inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 3c. What frequency of this therapy (zinc pyrithione shampoo) do you recommend/prescribe? | a. Daily |
| b. Three times a week | |
| c. Once a week | |
| d. As needed | |
| 4. Do you recommend/prescribe selenium sulfide shampoo for CCCA? | a. No |
| b. Yes | |
| If yes to Q4: | |
| 4a. How likely are you to recommend/prescribe this treatment (selenium sulfide shampoo)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 4b. How confident are you in the efficacy of this treatment (selenium sulfide shampoo) to treat scaling, itchiness, inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 4c. What frequency of this therapy (selenium sulfide shampoo) do you recommend/prescribe? | a. Daily |
| b. Three times a week | |
| c. Once a week | |
| d. As needed | |
| 5. Do you recommend/prescribe topical steroids for CCCA? | a. No |
| b. Yes | |
| If yes to Q5: | |
| 5a. Which topical steroid do you most commonly use? | a. Clobetasol solution/foam (Clobex) |
| b. Fluocinolone oil (Derma-smooth oil) | |
| c. Fluocinonide solution (Lidex) | |
| d. All of the above | |
| e. Other *Free response | |
| 5b. How likely are you to recommend/prescribe this treatment (topical steroids)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 5c. How confident are you in the efficacy of this treatment (topical steroids) to treat scaling, itchiness, inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 5d. What is the typical dosage of this therapy (topical steroids) that you recommend/prescribe? | a. Twice a day |
| b. Daily | |
| c. Three times a week | |
| d. Once a week | |
| e. As needed | |
| 6. Do you use intralesional steroids (Kenalog or triamcinolone) for CCCA? | a. No |
| b. Yes | |
| If yes to Q6: | |
| 6a. How likely are you to recommend/prescribe this treatment? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 6b. How confident are you in the efficacy of this treatment to treat scaling, itchiness, inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 6c. What concentration of this therapy (intralesional steroids) do you use? | a. TAC 5% |
| b. TAC 10% | |
| c. TAC 20% | |
| d. TAC 40% | |
| e. Other *Free response | |
| 6d. What is the typical dosage of this therapy (intralesional steroids) that you administer per visit? | f. <1mL |
| g. 1-3mL | |
| h. 3-5mL | |
| i. >5mL | |
| 7. Do you use topical minoxidil for CCCA? | a. No |
| b. Yes | |
| If yes to Q7: | |
| 7a. How likely are you to recommend/prescribe this treatment (topical minoxidil)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 7b. How confident are you in the efficacy of this treatment (topical minoxidil) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 7c. What percentage of this therapy (topical minoxidil) do you recommend/prescribe? | a. 2% |
| b. 5% | |
| c. >5% | |
| d. Other *Free response | |
| 7d. How often do you counsel your patients on the side effects of temporary hair shedding, irritation, and hypertrichosis associated with minoxidil use? | a. Always |
| b. Often | |
| c. Sometimes | |
| d. Not at all | |
| 8. Do you use oral minoxidil for CCCA? | a. No |
| b. Yes | |
| If yes to Q8: | |
| 8a. How likely are you to recommend/prescribe this treatment (oral minoxidil)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 8b. How confident are you in the efficacy of this treatment (oral minoxidil) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 8c. What is the typical dosage of this therapy that you prescribe? | a. 0.625mg (1/4 pill) daily |
| b. 1.25mg (1/2 pill) daily | |
| c. 2.5mg (full pill) daily | |
| d. 5mg (2 pills) daily | |
| 9. Do you use oral finasteride for CCCA? | a. No |
| b. Yes | |
| If yes to Q9: | |
| 9a. How likely are you to recommend/prescribe this treatment (oral finasteride)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 9b. How confident are you in the efficacy of this treatment (oral finasteride) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 9c. What is the typical dosage of this therapy (oral finasteride) that you prescribe? | a. 1mg daily |
| b. 5mg daily | |
| 10. Do you use oral antibiotics (tetracyclines) for CCCA? | a. No |
| b. Yes | |
| If yes to Q10: | |
| 10a. How likely are you to recommend/prescribe this treatment (oral antibiotics)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 10b. How confident are you in the efficacy of this treatment (oral antibiotics) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 10c. What is the typical dosage of this therapy (oral antibiotics) that you prescribe? | . *Free response |
| 11. Do you use in-office LED light therapy for CCCA? | a. No |
| b. Yes | |
| If yes to Q11: | |
| 11a. How likely are you to recommend/prescribe this treatment (LED light therapy)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 11b. What device and wavelength do you have in-office? | *Free response |
| 11c. How confident are you in the efficacy of this treatment (LED light therapy) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 11d. How frequently do patients come in for LED light therapy treatments? | a. Three times per week |
| b. Once per week | |
| c. Other *Free response | |
| 12. Do you use platelet-rich plasma (PRP) injections for CCCA? | a. No |
| b. Yes | |
| If yes to Q12: | |
| 12a.How likely are you to recommend/prescribe this treatment (PRP)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 12b. How confident are you in the efficacy of this treatment (PRP) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 12c. What PRP system do you use? | a. ProGen |
| b. Eclipse | |
| c. Emcyte | |
| d. PRFM- Selphyl | |
| e. Other *Free response | |
| 13. Do you use exosomes for CCCA? | a. No |
| b. Yes | |
| If yes to Q13: | |
| 13a. How likely are you to recommend/prescribe this treatment (exosomes)? | a. First line (every patient with CCCA) |
| b. Second line (after one therapy has been tried) | |
| c. Third line (after two therapies have been tried) | |
| d. With certain conditions *Free response | |
| 13b. How confident are you in the efficacy of this treatment (exosomes) to treat inflammation, and/or reduce hair loss? | a. Very confident (1) |
| b. Confident (2) | |
| c. Neutral (3) | |
| d. Not confident (4) | |
| e. Very not confident (5) | |
| 14. Do you use any compounded topical treatments for CCCA? | a. No |
| b. Yes | |
| If yes to Q14: | |
| 14a. If yes, which compounded topical treatments? | a. Clobetasol/minoxidil/tacrolimus |
| b. Tacrolimus | |
| c. Other *Free response | |
| 15. Any additional treatments you use for patients with CCCA, please list them here: | *Free response |
Disclosures
Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Albert Einstein College of Medicine Institutional Review Board issued approval 2022-14189.
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Janet Choi, Eliza Balazic, Christy Nwankwo, Kseniya Kobets
Acquisition, analysis, or interpretation of data: Janet Choi, Isabelle Ilan, Jin Ning Tian
Drafting of the manuscript: Janet Choi, Isabelle Ilan
Critical review of the manuscript for important intellectual content: Janet Choi, Jin Ning Tian, Eliza Balazic, Christy Nwankwo, Kseniya Kobets
Supervision: Kseniya Kobets
References
- 1.Beyond the hot comb: updates in epidemiology, pathogenesis, and treatment of central centrifugal cicatricial alopecia from 2011 to 2021. George EA, Matthews C, Roche FC, Taylor SC. Am J Clin Dermatol. 2023;24:81–88. doi: 10.1007/s40257-022-00740-w. [DOI] [PubMed] [Google Scholar]
- 2.Central centrifugal cicatricial alopecia. Aguh C, McMichael A. JAMA Dermatol. 2020;156:1036. doi: 10.1001/jamadermatol.2020.1859. [DOI] [PubMed] [Google Scholar]
- 3.Premature desquamation of the inner root sheath in noninflamed hair follicles as a specific marker for central centrifugal cicatricial alopecia. Tan T, Guitart J, Gerami P, Yazdan P. Am J Dermatopathol. 2019;41:350–354. doi: 10.1097/DAD.0000000000001336. [DOI] [PubMed] [Google Scholar]
- 4.Pathologic diagnosis of central centrifugal cicatricial alopecia on horizontal sections. Miteva M, Tosti A. Am J Dermatopathol. 2014;36:859–864. doi: 10.1097/DAD.0000000000000174. [DOI] [PubMed] [Google Scholar]
- 5.Medical and environmental risk factors for the development of central centrifugal cicatricial alopecia: a population study. Kyei A, Bergfeld WF, Piliang M, Summers P. Arch Dermatol. 2011;147:909–914. doi: 10.1001/archdermatol.2011.66. [DOI] [PubMed] [Google Scholar]
- 6.Association of type 2 diabetes with central centrifugal cicatricial alopecia: a follow-up study. Roche FC, Harris J, Ogunleye T, Taylor SC. J Am Acad Dermatol. 2022;86:661–662. doi: 10.1016/j.jaad.2021.02.036. [DOI] [PubMed] [Google Scholar]
- 7.Gabros S, Sathe NC, Masood S. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2025. Central centrifugal cicatricial alopecia. [PubMed] [Google Scholar]
- 8.Health care barriers and quality of life in central centrifugal cicatricial alopecia patients. Akintilo L, Hahn EA, Yu JMA, Patterson SSL. https://www.mdedge.com/dermatology/article/189437/hair-nails/health-care-barriers-and-quality-life-central-centrifugal. Cutis. 2018;102:427–432. [PubMed] [Google Scholar]
- 9.Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations. Jackson T, Sow Y, Dinkins J, et al. J Am Acad Dermatol. 2024;90:1182–1189. doi: 10.1016/j.jaad.2023.12.073. [DOI] [PubMed] [Google Scholar]
- 10.Safety and efficacy of clobetasol propionate 0.05% emollient foam for the treatment of central centrifugal cicatricial alopecia. Callender VD, Kazemi A, Young CM, Chappell JA, Sperling LC. J Drugs Dermatol. 2020;19:719–724. doi: 10.36849/JDD.2020.5201. [DOI] [PubMed] [Google Scholar]
- 11.Central centrifugal cicatricial alopecia: challenges and treatments. Lawson CN, Bakayoko A, Callender VD. Dermatol Clin. 2021;39:389–405. doi: 10.1016/j.det.2021.03.004. [DOI] [PubMed] [Google Scholar]
- 12.Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Fields JR, Vonu PM, Monir RL, Schoch JJ. Dermatol Ther. 2020;33:0. doi: 10.1111/dth.13202. [DOI] [PubMed] [Google Scholar]
- 13.Medical and surgical therapies for alopecias in Black women. Callender VD, McMichael AJ, Cohen GF. Dermatol Ther. 2004;17:164–176. doi: 10.1111/j.1396-0296.2004.04017.x. [DOI] [PubMed] [Google Scholar]
- 14.Minoxidil: mechanisms of action on hair growth. Messenger AG, Rundegren J. Br J Dermatol. 2004;150:186–194. doi: 10.1111/j.1365-2133.2004.05785.x. [DOI] [PubMed] [Google Scholar]
- 15.Central centrifugal cicatricial alopecia: challenges and solutions. Herskovitz I, Miteva M. Clin Cosmet Investig Dermatol. 2016;9:175–181. doi: 10.2147/CCID.S100816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. Araoye EF, Thomas JA, Aguh CU. JAAD Case Rep. 2020;6:106–108. doi: 10.1016/j.jdcr.2019.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Postepy Dermatol Alergol. 2013;30:165–169. doi: 10.5114/pdia.2013.35619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Anti-inflammatory activity of tetracyclines. Webster G, Del Rosso JQ. Dermatol Clin. 2007;25:133-5, v. doi: 10.1016/j.det.2007.01.012. [DOI] [PubMed] [Google Scholar]
- 19.Doxycycline for central centrifugal cicatricial alopecia: a single center retrospective analysis. Obi A, McKinley J, Oladunjoye E, et al. J Am Acad Dermatol. 2024;91:331–333. doi: 10.1016/j.jaad.2024.01.086. [DOI] [PubMed] [Google Scholar]
- 20.Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women. Oliveira-Soares R, André MC, Peres-Correia M. Int J Trichology. 2018;10:48–50. doi: 10.4103/ijt.ijt_73_15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Yasir M, Goyal A, Sonthalia S. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2025. Corticosteroid adverse effects. [PubMed] [Google Scholar]
- 22.Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR. https://pmc.ncbi.nlm.nih.gov/articles/PMC4126803/ Semin Cutan Med Surg. 2013;32:41–52. [PMC free article] [PubMed] [Google Scholar]
- 23.Use of low-level light therapy in management of central centrifugal cicatricial alopecia: a case series of four patients. Cook MK, Feaster BN, Subash JJ, Larrondo J, McMichael AJ. Photodermatol Photoimmunol Photomed. 2023;39:673–675. doi: 10.1111/phpp.12905. [DOI] [PubMed] [Google Scholar]
- 24.Platelet-rich plasma and its use for cicatricial and non-cicatricial alopecias: a narrative review. Alves R, Grimalt R. Dermatol Ther (Heidelb) 2020;10:623–633. doi: 10.1007/s13555-020-00408-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Systematic review of exosome treatment in hair restoration: preliminary evidence, safety, and future directions. Gupta AK, Wang T, Rapaport JA. J Cosmet Dermatol. 2023;22:2424–2433. doi: 10.1111/jocd.15869. [DOI] [PubMed] [Google Scholar]
- 26.Regulation of hair follicle development by exosomes derived from dermal papilla cells. Zhou L, Wang H, Jing J, Yu L, Wu X, Lu Z. Biochem Biophys Res Commun. 2018;500:325–332. doi: 10.1016/j.bbrc.2018.04.067. [DOI] [PubMed] [Google Scholar]
- 27.FDA: Consumer alert on regenerative medicine products including stem cells and exosomes. [ May; 2025 ];https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes 2020 26:2025. [Google Scholar]